Finding ways to overcome treatment resistance in pancreatic cancer
Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma
This study is looking into why pancreatic cancer is hard to treat and hopes to find new ways to make treatments work better by understanding how the cancer cells interact with their environment, which could help patients get more effective therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project ID | NIH-10883558 on NIH RePORTER |
What this research studies
This research focuses on understanding why pancreatic ductal adenocarcinoma (PDA) is so difficult to treat effectively. It investigates the tumor's unique environment, which limits drug delivery and promotes survival of cancer cells. By studying the interactions between tumor cells and their surroundings, the research aims to identify new strategies to enhance treatment responses and overcome resistance. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in targeting therapeutic resistance in other cancers, suggesting potential for success in this area as well.
Where this research is happening
La Jolla, UNITED STATES
- Salk Institute for Biological Studies — La Jolla, United States (Active)
Researchers
- Principal investigator: Hunter, Tony R. — Salk Institute for Biological Studies
- Study coordinator: Hunter, Tony R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.